Potential use of custirsen to treat prostate cancer

Celestia S Higano
Department of Medicine, University of Washington, and Fred Hutchinson Cancer Research Center, Seattle, WA, USA

Abstract: Over the last few years, five agents have demonstrated a survival benefit over a comparator treatment or placebo in the treatment of metastatic castration-resistant prostate cancer and have been approved by the US Food and Drug Administration: sipuleucel-T (a dendritic cell immunotherapy); cabazitaxel; abiraterone acetate and enzalutamide (both hormonal agents); and radium 223 (an alpha emitter). The development of these agents pivoted on whether patients had been treated with docetaxel, which remains the first-line chemotherapeutic of choice. To date, no combination of docetaxel and another active agent has demonstrated superiority to docetaxel alone despite numerous Phase III trials. Clusterin is a cytoprotective chaperone protein that is upregulated in response to various anticancer therapies. When overexpressed, clusterin interferes with apoptotic signaling, thereby promoting cell survival and conferring broad-spectrum resistance in cancer cell lines. Custirsen (OGX-011) is a second-generation 2′-methoxyethyl modified phosphorothioate antisense oligonucleotide that inhibits expression of clusterin. This review presents the preclinical and clinical data that provided the rationale for the combination of custirsen with chemotherapy in ongoing Phase III trials.

Keywords: castration-resistant prostate cancer, clusterin, custirsen, OGX-011, antisense, OGX-427, apoptosis

Introduction
Prostate cancer is the most common cancer affecting men in the US (excluding nonmelanoma skin cancers), and is the second leading cause of cancer death among men.1,2 It was estimated that in 2012 there were more than 240,000 new cases in the US.2

Most patients with hormone-sensitive recurrent or metastatic prostate cancer will develop castration-resistant disease over time. Prior to 2004, when the US Food and Drug Administration approved docetaxel, chemotherapy had a limited role in the routine treatment of metastatic castration-resistant prostate cancer (mCRPC). However, based on two Phase III trials in mCRPC, in which docetaxel conferred a modest survival improvement of 2–2.5 months compared with mitoxantrone and prednisone,3,4 docetaxel became and has remained the preferred first-line chemotherapeutic agent for mCRPC.5

A substantial proportion of patients in the Phase III registration studies for docetaxel did not respond to docetaxel,3,4 and many responses were of less than six months’ duration.4,6 This has prompted numerous attempts to improve on the outcomes of treatment with docetaxel. Docetaxel has been studied in combination with agents having
numerous mechanisms of action, including immunotherapy (granulocyte-macrophage colony-stimulating factor gene-transfected tumor cell vaccine), antiangiogenesis (bevacizumab, aflibercept and lenalidomide), endothelin receptor inhibition (atrasentan and zibotentan), vitamin D ligand-mediated potentiation (calcitriol), and tyrosine kinase (src) inhibition (dasatinib). None of these combinations has proven to be superior to standard docetaxel and prednisone alone.\(^7\)\(^{-14}\)

Since 2010, five additional agents, ie, sipuleucel-T, cabazitaxel, abiraterone acetate, radium 223, and enzalutamide, have shown a survival advantage in Phase III prostate cancer trials.\(^15\)\(^{-19}\) Sipuleucel-T, a dendritic cell immunotherapy, was compared with placebo either before or after docetaxel therapy in men who had no or minimal symptoms.\(^15\) Cabazitaxel, a taxane, was compared with mitoxantrone\(^16\) and was approved as second-line chemotherapy after docetaxel. Abiraterone acetate and enzalutamide, both hormonal agents, were compared with prednisone or placebo, respectively.\(^17\)\(^{19}\) Radium 223, an alpha emitter, was compared with best supportive care.\(^18\)

However, studies of the approved agents were conducted in either the pre-docetaxel or post-docetaxel setting, and none of these agents has been compared with docetaxel. Given the rapid entry of these new agents into the mCRPC treatment landscape, there is currently significant uncertainty about how to sequence therapy, and whether combinations of these agents confer additional benefits. Nonetheless, it is likely that chemotherapy will still play a significant role in the treatment of mCRPC, and hence strategies to augment the modest improvements in outcome are still needed. This article focuses on examining why clusterin is a rational target in mCRPC, and how strategies to augment the modest improvements in outcome are still needed. This article focuses on examining why clusterin is a rational target in mCRPC, and why the antisense molecule to clusterin, custisiren, is currently being studied in combination with chemotherapy (docetaxel or cabazitaxel) in Phase III trials in men with mCRPC.

**Role of clusterin in prostate cancer**

Molecular chaperones, eg, heat-shock proteins, are thought to interact with unfolded or partially folded cellular proteins to prevent inappropriate aggregation, aberrant folding, or denaturation. They play a key role in the cell’s response to stress and are also involved in regulating cell signaling and gene expression through their interactions with components of signal transduction pathways (reviewed by Gaestel\(^20\) and Vabulas et al\(^21\)). Uregulation of molecular chaperones in tumor cells has been implicated in the survival mechanisms used by tumor cells to evade apoptosis induced by cancer therapies.\(^22\)

Clusterin is an ATP-independent chaperone protein with structural similarity to the heat-shock proteins, and is known to be overexpressed in many solid tumors (reviewed by Zoubeidi et al\(^22\)). The clusterin gene is located on chromosome 8p21–p12,\(^24\) and is regulated by heat-shock factor-1. It encodes both cytoplasmic/secretory and nuclear forms of the protein (reviewed by Zoubeidi et al\(^23\)). The roles and function of the nuclear form have not been extensively studied, but the cytoplasmic/secretory forms of clusterin are known to be expressed in most tissues and contribute to many normal physiological processes as well as several diseases, including Alzheimer’s disease and cancer.\(^25\)\(^{-28}\) There is evidence that stressful stimuli can result in retention of clusterin in the cytosol.\(^29\)

Clusterin is thought to have multiple functions in the stress response and in cell survival pathways,\(^23\) but its mechanism of action is not yet fully understood. The cytoplasmic/secretory forms of clusterin include protein-folding and oligomerization motifs, such as coiled-coil domains.\(^23\) These are thought to mediate its interaction with other proteins and macromolecular complexes. Biochemical studies have confirmed that clusterin can prevent protein precipitation in vitro to protect cells from stress-induced changes,\(^30\) and also indicate a role for both secreted and cytosolic clusterin in the clearance of misfolded proteins.\(^29\)\(^{31,32}\) Clusterin demonstrates antiapoptotic activity in prostate cancer cells,\(^33\) and has been shown to interact with several key protein complexes known to be involved in apoptosis and cell survival pathways associated with tumor progression. These include the proapoptotic Bcl-2-associated protein Bax, which is inhibited by binding of clusterin to conformationally altered Bax in the Ku70–Bax complex.\(^34\) the COMMD1/1-κB complex, through which clusterin indirectly regulates nuclear factor (NF)-κB activity and signaling,\(^35\) the extracellular signal-regulated kinase ERK, and AKT kinase, which also acts upstream of NF-κB (Figure 1).\(^33\) A role for clusterin in tumor invasiveness and metastasis has also been proposed because of its interaction with the ERK/slug pathway (Figure 1) and its role in transforming growth factor-β-promoted epithelial-mesenchymal transition.\(^36\)

Overexpression of clusterin has been detected in many tumor types, including prostate, breast, non-small cell lung, colorectal, ovary, bladder, and renal cancers,\(^25\)\(^{-26,37-41}\) and it has been linked with more aggressive tumors and poorer outcomes.\(^26\)\(^{37,40} \) In prostate cancer, clusterin overexpression is associated with poor prognostic factors, such as high Gleason
Clusterin expression is known to be upregulated in patients with mCRPC after neoadjuvant hormone therapy, and in docetaxel-resistant prostate cancer cell lines. In experimental models, overexpression of clusterin in prostate cancer cell lines confers resistance to both antiandrogen therapy and chemotherapy with taxanes, and decreases radiosensitivity, with a concomitant decrease in radiation-induced apoptosis and arrest of growth. This evidence supports the hypothesis that clusterin plays a key role in the development of resistance to treatment by blocking therapy-induced apoptosis, and provides a strong rationale for targeting clusterin in prostate cancer.

**Targeting clusterin with antisense technology**

Antisense oligonucleotide (ASO) therapy targets specific functional genes. ASOs consist of single-strand DNA that is complementary to messenger (m)RNA expressed by the target gene. Binding of the ASO to mRNA creates a complex that inhibits translation of the mRNA and thus reduces levels of the protein encoded by the target gene. ASOs can also have “off-target” immunostimulatory effects related to certain sequences in the ASO. The phosphorothioate ASOs are water soluble and modified to resist nuclease digestion.

The use of ASOs to target synthesis of proteins involved in key steps of disease processes has been investigated in the clinic over the last few decades. The first-generation ASOs typically have short serum and tissue half-lives, and require continuous intravenous infusion. These pharmacologic properties led to limited success in the clinic, and a number of first-generation antisense approaches have failed to achieve regulatory approval to treat cancer. For example, oblimersen sodium, which inhibits bcl-2 expression, did not demonstrate a survival benefit in Phase III trials of melanoma or myeloma.
Another first-generation antisense agent, ISIS 3521 (an inhibitor of protein kinase c-α), did not meet its primary endpoint in a Phase III study in non-small cell lung cancer.52

Custirsen is a second-generation phosphorothioate ASO that binds to the translation initiation site of mRNA for human secretory clusterin. It differs from previous antisense approaches through the addition of 2′-methoxymethyl on the ribose groups of nucleotides at the ends of the phosphorothioate backbone (Figure 2).53 This modification is thought to confer higher affinity for the target RNA54 and improved resistance to nucleases, with a correspondingly prolonged tissue half-life of approximately seven days and hence a more convenient dosing schedule than first-generation ASOs.55 There is also some evidence suggesting that second-generation ASOs with 2′-methoxymethyl modifications are less toxic and cause less nonspecific immune stimulation than unmodified ASOs.55 This may enable the use of higher doses.

OGX-427, which targets heat-shock protein 27, is another second-generation antisense agent with the 2′-methoxymethyl modification. OGX-427 has shown promising antitumor effects in early clinical studies in both prostate and bladder cancers.56–58 LY2181308, a second-generation antisense agent that targets the cell survival protein survivin, has demonstrated activity in a Phase I study of patients with solid tumors.59

Preliminary results in early phase studies suggest that, despite discouraging results with the first-generation antisense agents in cancer therapy, the improved pharmacokinetics of the second-generation antisense agents might result in improved outcomes using this approach.

**Preclinical studies of custirsen**

In vitro and in vivo experiments in various cancer cell lines confirm potent suppression of clusterin mRNA and protein levels by custirsen.45,53,60,61 In a docetaxel-resistant prostate cancer cell line and xenograft model (PC-3), addition of custirsen increased the rate of apoptosis and resensitized cells to docetaxel and paclitaxel (Figure 3).45,53 In animal models of prostate cancer, custirsen has been shown to increase apoptosis and resensitize treatment-resistant tumors to radiation, chemotherapy, and hormone therapy.45,62 Similar effects have been observed in other tumor types, including breast, lung, and bladder.61,63,64

**Efficacy of custirsen in clinical trials in prostate cancer**

To date, over 500 patients have been treated with custirsen in a comprehensive clinical development program encompassing multiple tumor types (prostate, breast, and non-small cell lung) and clinical settings (neoadjuvant, first-line, and second-line treatment in different combination regimens). A summary of published clinical trials of custirsen in prostate cancer is presented in Table 1.

**Phase I studies of custirsen**

The first-in-human Phase I study established that custirsen was well tolerated with a predictable pharmacokinetic profile, and that there was a dose-dependent inhibition of clusterin expression with an associated increase in apoptotic index in primary prostate cancer tissue.65 Twenty-five patients with previously untreated localized disease and high-risk features (prostate-specific antigen [PSA] >10 ng/mL, stage T3 disease, Gleason score 7–10) who were candidates for radical prostatectomy were treated with androgen deprivation and custirsen by two-hour intravenous infusion on days 1, 3, and 5, followed by weekly dosing, starting on day 8, for four doses. Custirsen was administered in six dose cohorts of 40, 80, 160, 320, 480, and 640 mg. Prostatectomy was performed within seven days of the final dose of custirsen. No dose-limiting toxicity was observed at the maximum dose level of 640 mg. Both the area under the plasma concentration-time curve and the maximum plasma concentration of custirsen increased proportionally with dose. Custirsen concentrations

---

**Figure 2** Structure of the 21-mer custirsen antisense oligonucleotide to clusterin mRNA.

in prostate tissue also increased with dose. This study provided the first clinical evidence for the biological effect of custirsen, with dose-dependent decreases in clusterin expression of >90% demonstrated in both prostate tissue and lymph nodes, and an associated significant increase in the apoptotic index in prostatectomy specimens (Figure 4). Based on the results of this study, the dose of 640 mg was selected as a well tolerated and biologically active dose for evaluation in Phase II studies.

A Phase I study was undertaken to define the recommended dose of custirsen in combination with docetaxel. Forty patients with solid tumor types known to overexpress clusterin (prostate, ovary, renal, non-small cell lung, bladder, breast) and with metastatic or locally recurrent disease refractory to curative therapy were enrolled. Custirsen was administered using the same schedule as in the single-agent Phase I study, with loading doses followed by weekly doses of custirsen using the same dose-escalation scheme. Two dose schedules for docetaxel were studied. Schedule A was docetaxel 30 mg/m² weekly for five of six weeks per cycle for up to four cycles. After the recommended dose of custirsen with weekly docetaxel was established in schedule A, custirsen was studied with three-weekly docetaxel 75 mg/m² (schedule B), starting at one dose level below the recommended custirsen dose identified in schedule A. The recommended single-agent custirsen dose of 640 mg was well tolerated when administered with either weekly or three-weekly standard docetaxel. Again, dose-dependent decreases in clusterin were noted, with the maximum decrease at the 640 mg dose of custirsen. Serum clusterin levels remained decreased from baseline by 38% and 34% with schedule A and B, respectively. Among the patients in the study with CRPC (n = 15), two had a confirmed partial response (based on Response Evaluation Criteria in Solid Tumors) and six had a confirmed PSA response (defined as a ≥50% decline from the baseline level). This study established 640 mg as the recommended Phase II dose for custirsen in combination with docetaxel for prostate cancer and other solid tumors, including breast and lung cancers.

**Phase II studies**

**Neoadjuvant use in prostate cancer**
A study of 24 patients with localized prostate cancer and high-risk features was conducted to determine the pathologic complete response rate with androgen deprivation therapy and 12 weeks of custirsen 640 mg weekly. Although there
Table I  Summary of published clinical trials on custirsen in prostate cancer

<table>
<thead>
<tr>
<th>Study design (clinicaltrials.gov identifier)</th>
<th>Treatment</th>
<th>Patients (n)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neoadjuvant</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phase I</td>
<td>Custirsen 40, 80, 160, 320, 480, or 640 mg IV loading dose on days 1, 3, and 5, then weekly from day 8 to 29 plus buserelin acetate 6.3 mg injection on day 1 and flutamide 250 mg oral tid for 28 days. Prostatectomy took place from days 30–36</td>
<td>25</td>
</tr>
<tr>
<td>Phase II</td>
<td>Custirsen 640 mg IV loading dose on days 1, 3, and 5, then weekly for 12 weeks plus buserelin acetate and flutamide. Prostatectomy took place within 2 weeks of the last dose</td>
<td>24</td>
</tr>
<tr>
<td>First-line</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Randomized Phase II</td>
<td>Docetaxel 75 mg/m² IV 3-weekly and oral prednisone 5 mg bid plus custirsen 640 mg IV (three loading doses during week -1 followed by weekly doses) for up to 10 cycles</td>
<td>41</td>
</tr>
<tr>
<td></td>
<td>Docetaxel 75 mg/m² 3-weekly and oral prednisone 5 mg bid</td>
<td>41</td>
</tr>
<tr>
<td>Second-line</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Randomized Phase II</td>
<td>Docetaxel 75 mg/m² IV 3-weekly and oral prednisone 5 mg bid plus custirsen 640 mg IV (three loading doses on week -1 followed by weekly doses) for up to 9 cycles</td>
<td>20</td>
</tr>
<tr>
<td></td>
<td>Mitoxantrone 12 mg/m² IV 3-weekly and oral prednisone 5 mg bid plus custirsen 640 mg IV (three loading doses on week -1 followed by weekly doses) for up to 9 cycles</td>
<td>22</td>
</tr>
</tbody>
</table>

were no pathologic complete responses, tissue custirsen levels were $>1 \mu g/g$, the level at which preclinical effects were seen. In addition, the data confirmed the effects of custirsen on clusterin expression and apoptotic index previously described in the Phase I study of localized disease.

First-line use in combination with docetaxel

A randomized Phase II study investigated the effect of docetaxel 75 mg/m² and prednisone 5 mg twice daily with (arm A) and without (arm B) custirsen 640 mg weekly. Eighty-two men with mCRPC who were chemotherapy-naïve were accrued, with 41 patients in each arm. The primary endpoint was a PSA decline of $\geq 50\%$ from baseline. This occurred in 58% of patients in arm A and in 54% of patients in arm B (Table 1). In patients with measurable disease, partial responses were noted in 19% and 25% of patients in arms A and B, respectively. Median progression-free survival was 7.3 months versus 6.1 months and overall survival was 23.8 months versus 16.9 months in arms A and B, respectively, with an unadjusted hazard ratio of 0.61 (95% confidence interval 0.36–1.02) for overall survival. Serum clusterin levels had decreased by a median of 26% at the end of the first treatment cycle in arm A, whereas they had increased by a median of 1% in patients in arm B.

Although the rate of patients achieving a PSA decline of $\geq 50\%$ from baseline was not significantly improved with...
the combination, this study demonstrated that addition of custirsen to docetaxel hit the target, as evidenced by the decrease in clusterin levels compared with no change in arm B. Based on the mechanism of action of custirsen, it was not unexpected that there was no difference observed in the response rates between the two treatment arms in this study. Only those patients with high pretreatment levels of clusterin would be expected to benefit from custirsen, given that patients with low levels of clusterin would normally respond well to chemotherapy alone. However, this was a small Phase II study and was not powered for exploratory analyses. The small number of patients with measurable disease progression in arm A compared with arm B is of interest. In addition, treatment may have been stopped before it was possible to demonstrate a benefit for custirsen in terms of progression-free survival, and a delay in progression may have contributed to the overall survival benefit observed for custirsen. The suggestion of improved overall survival, overall tolerability, and biological effect of the combination provided the basis for further exploration of the combination in Phase III studies in mCRPC.

Second-line use in combination with docetaxel or mitoxantrone
The preclinical finding that custirsen resensitizes docetaxel-refractory prostate cancer cells led to initiation of a

<table>
<thead>
<tr>
<th>Survival (median)</th>
<th>Response rate</th>
<th>PSA change from baseline</th>
<th>Other relevant findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>• Dose-dependent increase in custirsen concentrations in prostate tissue</td>
</tr>
<tr>
<td>NR</td>
<td>pCR, 0%</td>
<td>NR</td>
<td>• Dose-dependent decrease in clusterin expression of 74% in prostate tissue and lymph nodes, compared with historical controls</td>
</tr>
<tr>
<td><strong>OS, 23.8 months</strong></td>
<td><strong>Number evaluable, 26</strong></td>
<td><strong>≥30%, 65%</strong></td>
<td>• Increase in apoptotic index of prostatectomy specimens (mean 21.2% versus 7–9% for historical controls)</td>
</tr>
<tr>
<td><strong>PFS, 7.3 months</strong></td>
<td><strong>CR, 0%</strong></td>
<td><strong>≥50%, 58%</strong></td>
<td>• Custirsen concentrations in prostate tissue &gt;1 μg/g</td>
</tr>
<tr>
<td><strong>SD, 19%</strong></td>
<td><strong>PR, 19%</strong></td>
<td></td>
<td>• Mean clusterin mRNA expression in prostate tissue was decreased by 51% versus historical controls</td>
</tr>
<tr>
<td><strong>PD, 4%</strong></td>
<td></td>
<td></td>
<td>• Increase in apoptotic index of prostatectomy specimens (mean 12.6% versus 7.6% for historical controls)</td>
</tr>
<tr>
<td><strong>OS, 16.9 months</strong></td>
<td><strong>Number evaluable, 24</strong></td>
<td><strong>≥30%, 59%</strong></td>
<td>• Serum clusterin levels decreased from baseline by a median of 26% at end of first cycle with docetaxel and prednisone and custirsen</td>
</tr>
<tr>
<td><strong>PFS, 6.1 months</strong></td>
<td><strong>CR, 0%</strong></td>
<td><strong>≥50%, 54%</strong></td>
<td>• Serum clusterin levels increased from baseline by a median of 0.9% at end of first cycle with docetaxel and prednisone alone</td>
</tr>
<tr>
<td><strong>SD, 50%</strong></td>
<td><strong>PR, 25%</strong></td>
<td></td>
<td>• Clusterin levels during treatment were reduced from baseline by a mean of 26% in the evaluable study population (n = 40)</td>
</tr>
<tr>
<td><strong>PD, 17%</strong></td>
<td></td>
<td></td>
<td>• 31/40 (78%) of evaluable patients achieved serum clusterin levels of ≤45 μg/mL</td>
</tr>
<tr>
<td><strong>OS, 15.8 months</strong></td>
<td><strong>Number evaluable, 13</strong></td>
<td><strong>≥30%, 55%</strong></td>
<td>• 28/40 (70%) of evaluable patients classified as responders*</td>
</tr>
<tr>
<td><strong>PFS, 7.2 months</strong></td>
<td><strong>PR, 15%</strong></td>
<td><strong>≥50%, 40%</strong></td>
<td>• Median time to clusterin response approximately 30 days</td>
</tr>
<tr>
<td><strong>SD, 69%</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>PD, 9%</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>OS, 11.5 months</strong></td>
<td><strong>Number evaluable 7</strong></td>
<td><strong>≥30%, 32%</strong></td>
<td></td>
</tr>
<tr>
<td><strong>PFS, 3.4 months</strong></td>
<td><strong>SD, 71%</strong></td>
<td><strong>≥50%, 27%</strong></td>
<td></td>
</tr>
</tbody>
</table>

Notes: *Cluster responders defined as patients with three successive clusterin levels during therapy = median baseline clusterin for the population.

Abbreviations: bid, twice daily; CR, complete response; IV, intravenous; mCRPC, metastatic castration-resistant prostate cancer; mRNA, messenger RNA; NR, not reported; OS, overall survival; pCR, pathologic complete response; PD, progressive disease; PFS, progression-free survival; PR, partial response; PSA, prostate-specific antigen; SD, stable disease; tid, three times daily.
randomized Phase II trial (Canadian Urologic Oncology Group [CUOG] trial P-06) of patients with mCRPC who had progressed within six months of first-line chemotherapy with docetaxel. Patients were randomized to treatment with custirsen 640 mg weekly with docetaxel 75 mg/m² and prednisone 5 mg twice daily every three weeks (DPC; n = 20), or custirsen with mitoxantrone 12 mg/m² and prednisone 5 mg twice daily every three weeks (MPC; n = 22). The primary endpoint was safety, and measures of efficacy were exploratory.

The combination of custirsen with either docetaxel or mitoxantrone was well tolerated. With the exception of fatigue and lymphopenia, the toxicities were similar to those seen with first-line docetaxel therapy in the TAX 327 trial. Lymphopenia is a known class effect of antisense agents and was seen in approximately one-third of patients but without infectious sequelae. Median overall survival for the DPC arm was 15.8 months versus 11.5 months for the MPC arm, and median progression-free survival was 7.2 months and 3.4 months, respectively. More patients in the DPC arm had PSA declines of $\geq 50\%$ and $\geq 90\%$ compared with those in the MPC arm (Table 1). For comparison, patients treated with first-line docetaxel in the TAX 327 study who crossed over to second-line mitoxantrone therapy during follow-up had a median overall survival of 10 months and median progression-free survival (defined by PSA progression) of 3.4 months. A study of patients who received rechallenge with docetaxel as second-line chemotherapy reported a median overall survival of 9.6 months and median time to symptom progression of 4.9 months.

Notes: Boxes represent interquartile ranges, and lines extending from the boxes represent the closer of 1.5 times the interquartile range, or the most extreme observation. Lines across the boxes represent the median, and circles represent outliers. Reproduced from Chi KN, Eisenhauer E, Fazli L, Jones EC, Goldenberg SL, Powers J, Tu D, Gleave M. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. *Journal of the National Cancer Institute*. 2005;97(17):1287–1296, by permission of Oxford University Press. Abbreviations: <2M NHT, less than two months of neoadjuvant hormone therapy; NT, no prior treatment.

Figure 4 Biological effects of custirsen (OGX-011) on clusterin expression and apoptotic index in prostate tumor cells from prostatectomy specimens. (A) Box plot of clusterin protein levels in prostate tumor samples from men treated with custirsen and untreated historical controls. (B) Apoptotic index (percentage apoptotic cells and bodies per 10 high-power fields) in prostatectomy specimens and untreated historical controls.
with those reported for second-line treatment with cabazitaxel (median overall survival 15.1 months). 16

Overall, 88% of patients in CUOG Trial P-06 had a durable (≥3 months) pain response. Of 13 evaluable patients in each treatment group, 77% of those in the DPC group responded with a median time to pain progression of 10.0 months compared with 46% of patients in the MPC group with a median time to pain progression of 5.2 months. As was observed in the other clinical studies, serum clusterin levels were reduced during treatment, and 70% of 40 evaluable patients were classified as clusterin responders. Low serum clusterin (≤median baseline level for the study population) during treatment was shown to be associated with improved survival, with a 70% reduction in the hazard of death at the time of response ($P < 0.001$). In addition, median overall survival for patients with minimum serum clusterin levels during treatment below the median minimum levels for the population (n = 22) was 14.9 months versus 9.9 months for those patients (n = 18) with levels above the median minimum ($P = 0.03$; Figure 5). For those patients who achieved the minimum threshold clusterin levels of 45 μg/mL (n = 33), median overall survival was 15 months versus 4.5 months for those who did not achieve this level (n = 7, $P < 0.001$; Figure 5).

The findings of this study showed that the combination of custirsen with either docetaxel and prednisone or mitoxantrone and prednisone is feasible in patients who have previously progressed during or after docetaxel chemotherapy, some of whom may have had tumors refractory to docetaxel. The relationship between clusterin levels and survival seen in this study suggests that serum clusterin is a potential biomarker of response to custirsen.

**Tolerability of custirsen**

In the first Phase I study of custirsen in prostate cancer, no dose-limiting toxicities were reported at the doses of custirsen investigated (up to 640 mg); all toxicities were grade 1/2 and typically occurred within the first week of administration. 65 For patients receiving the 640 mg dose, the most frequent adverse events included thrombocytopenia, anemia, and leukopenia, and nonhematologic toxicities, such as fever, fatigue, rigors, and elevation of aspartate/alanine aminotransferase. This toxicity profile is similar to that of other ASOs and many of these toxicities are thought to be due to nonsequence-specific effects of these compounds. 72,73

A second Phase I study of custirsen in combination with weekly or three-weekly docetaxel in patients with advanced cancer found the combination to be well tolerated, with mainly mild or moderate toxicity. 69 In this study, four of the 16 patients in the 640 mg dose groups experienced dose-limiting toxicities (dyspnea/pleural effusion, neutropenia, fatigue, and mucositis). Grade 1 or 2 adverse events that occurred most frequently at the 640 mg dose level included anemia, rigors, fatigue, fever, diarrhea, nausea/vomiting, alopecia, anorexia, mucositis, and elevated hepatic enzymes. Many of the observed toxicities overlap the expected effects of docetaxel, including myelosuppression, fatigue, alopecia, mild/moderate diarrhea, mucositis, fevers, and rigors.
In Phase II studies, custirsen was well tolerated in combination with docetaxel and prednisone, or with mitoxantrone and prednisone. The toxicities reported with the DPC combination\(^7\) were consistent with the Phase I results. Frequent grade 1/2 nonhematologic adverse events observed with DPC included fatigue (90%), sensory neuropathy (65%), rigors/chills (50%), diarrhea (58%), fever (50%), nausea (43%), and myalgia (40%). Fever, rigors, and diarrhea were considered to be related to custirsen, and in most cases the fever and rigors occurred during the first or second loading dose and were of less than 24 hours’ duration. Grade 3 or 4 lymphopenia was reported more frequently in the group receiving DPC (53% versus 22% for docetaxel and prednisone), but was not associated with a higher rate of infection. In the second Phase II trial, in which custirsen was combined with either docetaxel and prednisone or mitoxantrone and prednisone,\(^6,8\) >90% of adverse events were grade 1 or 2 and were generally similar between the two arms. The most frequent adverse events included fatigue (64%), chills (50%), nausea (50%), fever (40%), and diarrhea (36%). Fatigue and lymphopenia were the most frequent serious adverse events, affecting 29% and 31% of all patients, respectively. The rates of other grade 3/4 adverse events reported with the DPC combination in these Phase II studies compare favorably with rates reported in previous studies of docetaxel as first-line or second-line therapy for mCRPC,\(^1,7,0\) suggesting that addition of custirsen to docetaxel chemotherapy does not increase the serious toxicities associated with docetaxel therapy.

**Ongoing Phase III studies in prostate cancer**

The ongoing Phase III custirsen program in prostate cancer was designed on the basis of preclinical and clinical evidence for activity. Currently, there are two randomized, global Phase III trials of custirsen in combination with chemotherapy compared with the chemotherapy regimen alone. These trials will establish whether custirsen does in fact modulate taxane resistance and improve outcomes such as progression-free survival and overall survival compared with chemotherapy alone. In addition, both trials will measure serum clusterin levels as a potential predictive biomarker. The SYNERGY trial (NCT01188187) is a randomized, open-label study evaluating first-line therapy with custirsen in combination with docetaxel-prednisone versus docetaxel-prednisone alone in men with mCRPC who are chemotherapy-naive.\(^7,4\) The primary endpoint is overall survival. The trial has fully accrued its target, with over 1000 patients enrolled. It is anticipated that survival data will be announced by the first half of 2014. The AFFINITY trial (NCT01578655) is a randomized, open-label trial investigating the survival benefit with second-line treatment after first-line docetaxel with cabazitaxel 25 mg/m\(^2\) and prednisone 10 mg/day alone or in combination with custirsen 640 mg weekly. Approximately 630 patients with mCRPC who have progressed after first-line docetaxel will be recruited. This study is expected to be completed by the end of 2015.

**Custirsen in non-small cell lung cancer**

A Phase III trial known as ENSPIRIT (NCT01630733) is comparing docetaxel against docetaxel and custirsen as second-line treatment in 1100 patients with advanced or metastatic non-small cell lung cancer who have failed platinum-based therapy. The primary endpoint is overall survival. The study was initiated in September 2012 and is estimated to be completed by July 2017.

**Conclusion**

Clusterin is a cytoprotective chaperone protein that is overexpressed in many tumor types, and is upregulated in response to cellular stress caused by cancer treatments, including hormonal manipulation, radiation, and chemotherapy. Clusterin promotes cell survival during cellular stress and protects against treatment-induced apoptosis. Hence, targeting clusterin is a rational approach to overcoming resistance to cancer therapy. Custirsen is a second-generation ASO that is complementary to clusterin mRNA and potently suppresses clusterin expression in preclinical models of prostate cancer as well as in clinical trials. Prior to embarking on Phase III trials with custirsen, preclinical data were verified in numerous clinical trials. The innovative first-in-human Phase I neoadjuvant trial demonstrated dose-dependent plasma and prostate tissue concentrations of custirsen, which was well tolerated at all dose levels. Importantly, dose-dependent inhibition of clusterin expression was associated with an increase in apoptotic index, demonstrating proof of principle in humans. After a Phase II study of the 640 mg dose had confirmed the tolerability and activity of single-agent custirsen, it was combined with docetaxel to establish the recommended Phase II dose, based on tolerability and maximal inhibition of serum clusterin levels. Subsequently, a randomized Phase II trial compared the combination of docetaxel and custirsen with docetaxel alone. The results of this trial showed that the combination decreased serum clusterin levels, and there was a
suggestion that overall survival and progression-free survival were improved in comparison with docetaxel alone.

The ongoing Phase III trials of chemotherapy in combination with custirsen versus chemotherapy alone will define whether this combination actually does improve outcomes (overall survival and event-free survival after six cycles of chemotherapy) in mCRPC where so many other docetaxel combination regimens have failed. These Phase III trials will also assess the potential validity of clusterin as a predictive biomarker. Given the role of clusterin in cell survival in response to hormonal or radiation therapy, future trials combining custirsen with these modalities are warranted.

Disclosure

The author has received clinical trials research funding from OncoGenex, Teva, Aragon Pharmaceuticals, Medivation Inc, Algeta, and Dendreon, and has acted as a consultant for Aragon Pharmaceuticals, Astellas Pharma, Bristol-Myers Squibb, Bayer, Dendreon, and Teva. Medical writing support was provided by Kirsteen Munn of Anthemis Consulting Ltd and funded by Teva Pharmaceutical Industries, Frazer, PA. OncoGenex and Teva each provided a single medical accuracy review of the final draft. The author was not compensated and retained full editorial control over the content of the paper.

References


